Comparison Between Standard and High Dose of G-CSF for Mobilization of Hematopoietic Progenitors Cells in Patients and Healthy Donors

A standard dose of 10 pg/kg/day granulocyte colony stimulating factors (G-CSF) is currently recommended for hematopoietic progenitor cells (HPCs) mobilization. Our aim was to analyze whether certain patients or healthy donors could benefit from high dose of G-CSF.We performed a retrospective multicenter anal-ysis of HPCs mobilization procedures (2015-2020) in patients and healthy donors. Those who received standard dose of G-CSF (10 pg/Kg/day for 4 days to patients and healthy donors) and those that received higher dose (24 pg/Kg/day for 4 days to patients and 16 pg/Kg/day for 4 days to healthy donors) were compared.496 individuals were included (201 standard dose and 295 higher dose). Between standard or higher dose, we did not find significant differences in median number of mobilized CD34 + cells/mL, nei-ther among healthy donors (77 100 vs 75 500 respectively, P = .895), nor in patients (34 270 vs 33 704 respectively, P = .584). Additionally, among those with the same underlaying pathology the comparison between standard and higher dose did not showed differences. High G-CSF dose was not associated with a less frequent incidence of poor mobilizers ( < 20 0 0 0 CD34 + cells/mL) neither in healthy donors (1 [1.3%] vs 0; P = .218) nor patients (30 [24.4%] vs 32 [18.1%]; P = .165). Multivariate analysis showed that age, gender, and G-CSF dose did not influence median number of mobilized CD34 + cells/mL in healthy donors or patients. However, the underlying pathology among patients significantly influenced the CD34 + cells mobilization. In healthy donors, cellular blood count showed significantly higher leukocytes and platelets count with G-CSF high-dose, while in patients just a higher platelets count was found. To conclude, high dose of G-CSF compared to standard dose did not show significant benefit in terms of mobilization of CD34 + cells in healthy donors or in patients, also without a decrease in the incidence of poor mobilizers.(c) 2022 Elsevier Inc. All rights reserved.

Automated summary

A retrospective multicenter analysis of HPCs mobilization procedures was conducted to investigate the potential benefits of high dose G-CSF. The results showed that compared to the standard dose, high dose G-CSF did not significantly improve the mobilization of CD34+ cells in healthy donors or patients, and did not reduce the incidence of poor mobilization.